Drug-coated balloon in the treatment of coronary bifurcation lesions: A hope or hype?

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials in Medicine

Background:

• Percutaneous coronary intervention (PCI) for coronary bifurcation lesions is challenging, with historically lower success rates than non-bifurcation lesions.
• Drug-eluting stents have improved outcomes, but complex two-stent techniques can lead to side branch restenosis.
• The complexity of bifurcation anatomy and potential impact on coronary flow dynamics necessitate innovative treatment approaches.

Purpose of the Study:

• To review the current knowledge and future prospects of using drug-coated balloons (DCB) for treating coronary bifurcation lesions.
• To explore the potential of DCB as a less invasive alternative to stenting in complex bifurcation scenarios.
• To evaluate the benefits of reducing metallic burden in bifurcation interventions.

Main Methods:

• Review of existing literature on percutaneous coronary intervention for bifurcation lesions.
• Analysis of studies utilizing drug-coated balloons (DCB) in both main branch (MB) and side branch (SB) of bifurcations.
• Discussion of the technical aspects and clinical outcomes associated with DCB treatment in this complex anatomy.

Main Results:

• The provisional stenting technique remains the default for most bifurcation lesions, but complex cases may benefit from alternative strategies.
• Drug-coated balloons (DCB) have emerged as a viable option for treating bifurcation lesions, offering a "no permanent implant" approach.
• DCB use in bifurcations aims to reduce metallic burden and potentially mitigate risks of in-stent restenosis and flow dynamics compromise.

Conclusions:

• Drug-coated balloons (DCB) represent a significant advancement in the treatment of coronary bifurcation lesions, particularly in complex cases.
• DCB offer a compelling alternative to traditional stenting, potentially improving procedural success and long-term clinical results by minimizing metallic implants.
• Further research and clinical trials are warranted to fully establish the role and long-term efficacy of DCB in managing coronary bifurcation disease.